FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
Blum Holdings Inc. Reports Remarkable 2024 Financial Results with $33.1 Million in Net Income
Net Income: $33.1 million, representing an astonishing turnaround from a net loss of $14.1 million in 2023 and a net loss of $188.7 million in 2022, reflecting the successful restructuring and cost ...